Skip to main content

Table 3 Changes in SPARC expression over time

From: SPARC expression in patients with high-risk localized soft tissue sarcoma treated on a randomized phase II trial of neo/adjuvant chemotherapy

Histology

Primary site

Primary SPARC score

Treatment prior to primary score

Local (L) or distant (D) recurrence

Secondary SPARC score

Treatment prior to secondary score

MPNST

Extremity

0

AI

D

0

AD

SS

Extremity

0

GT, XRT

D

0

None

MPNST

Extremity

1

AI

L

0

None

UPS

Extremity

1

AI

D

2

GT

LMS

Trunk

1

AI, XRT

D

0

GT

UPS

Trunk

2

GT

L

2

None

UPS

Trunk

2

AI

L

4

None

Fibrosarcoma

Extremity

4

AI

L

6

None

Dediff LPS

Trunk

6

GT

D

4

None

UPS

Extremity

9

GT

D

0

None

  1. A- doxorubicin, I- ifosfamide, G-gemcitabine, T- docetaxel, D- dacarbazine